VTX 958
Alternative Names: TYK2 inhibitor-Ventyx Biosciences; VTX-958Latest Information Update: 01 Aug 2024
At a glance
- Originator Ventyx Biosciences
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Crohn's disease
- Research Autoimmune disorders
- Discontinued Plaque psoriasis; Psoriatic arthritis
Most Recent Events
- 30 Jul 2024 Interim efficacy and adverse events data from a phase II HARMONY trial in Crohn's disease released by Ventyx Biosciences
- 02 Jan 2024 Ventyx Biosciences terminates the phase-II Tranquility-PsA trial in Psoriatic arthritis in USA, Spain, Poland, Hungary, Germany, Czech Republic, Bulgaria (PO) (NCT05715125)
- 20 Dec 2023 Ventyx Biosciences terminates a phase II-SERENITY (Serenity PsO) trial in Plaque psoriasis in USA, Canada, Poland (PO) due to business decision (NCT05655299) (EudraCT2022-002887-59)